eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2020
vol. 71
 
Share:
Share:
more
 
 
abstract:
Original paper

Evaluation of CXCL12 and CXCR4 to predict poor survival in lymph node-positive colorectal cancer patients

Mehmet Zengin
1
,
Nevra Dursun
2
,
Kemal Behzatoğlu
3
,
Hüsniye Esra Paşaoğlu
4
,
Suat Benek
5

1.
Kırıkkale University Faculty of Medicine, Department of Pathology, Kırıkkale, Turkey
2.
Istanbul Education and Research Hospital, Department of Pathology, Istanbul, Turkey
3.
Acıbadem University Faculty of Medicine, Department of Pathology, Istanbul, Turkey
4.
Bağcılar Training and Research Hospital, Department of Pathology, Istanbul, Turkey
5.
Tekirdağ University Faculty of Medicine, Department of General Surgery, Istanbul, Turkey
Pol J Pathol 2020; 71 (4): 328-338
Online publish date: 2021/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
It is well known that interactions in the tumour microenvironment are very important in the progression of tumours. We investigated the relationship between chemokine ligand type 12 (CXCL12), chemokine receptor type 4 (CXCR4) and survival in advanced colorectal cancers (CRC). Primary tumour samples of stage III-IV CRC patients were investigated for CXCL12 and CXCR4. Chemokine ligand type 12 and CXCR4 expressions were significantly associated with poor prognostic factors (e.g. for CXCL12: lymphatic invasion [p = 0.009], positive surgical margin [p = 0.006], advanced stage [p = 0.028], etc.). Also, these parameters were independent risk factors for low LIR (e.g. for CXCL12: Odds ratio [OR] = 2.27, p = 0.001) and low tumour stroma-ratio (TSR; e.g. for CXCL12: OR = 1.18, p = 0.003). In univariate analysis, 5-year RFS and OS were poor (e.g. for CXCL12: RFS, p < 0.001 and OS, p = 0.001). Multivariate analysis showed that these parameters were independent poor survival parameters for RFS and OS (e.g. for CXCL12: Hazard ratio [HR] = 3.54 [CI: 1.52-4.67], p = 0.001 and HR = 2.74 [1.48-4.71], p = 0.025). We showed that CXCL12 and CXCR4 expressions are poor prognostic factors in lymph node-positive CRC patients and are associated with low TSR and low LIR.
keywords:

colorectal cancers, CXCL12, CXCR4, prognostic markers, stage III-IV

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe